Rifkin-Zybutz, Raphael
Erridge, Simon
Holvey, Carl
Coomber, Ross
Gaffney, Jessica
Lawn, Will
Barros, Daniela
Bhoskar, Urmila
Mwimba, Gracia
Praveen, Kavita
Symeon, Chris
Sachdeva-Mohan, Simmi
Rucker, James J
Sodergren, Mikael H
Funding for this research was provided by:
National Institute for Health and Care Research (ACF-2021-17-018, CS-2017-17-007)
Article History
Received: 28 December 2022
Accepted: 1 June 2023
First Online: 14 June 2023
Declarations
:
: Formal ethical approval for the UK Medical Cannabis Registry has been provided by the Health Research Authority (South West–Central Bristol Research Ethics Committee reference 22/SW/0145). All conditions as previously stated by the ICMJE have been met.
: All participants completed written and informed consent prior to enrolment in the registry.
: Dr Raphael Rifkin-Zybutz (Academic Clinical Fellow, ACF-2021-17-018) is funded by Health Education England (HEE)/NIHR for this research project. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR (Partner Name), NHS or the UK Department of Health and Social Care.Simon Erridge is a junior doctor and is the head of research at Sapphire Medical Clinics. Simon Erridge is an honorary clinical research fellow at Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS. Simon Erridge has no shareholdings in pharmaceutical companies.Jess Kerr-Gaffney is a post-doctoral researcher at King’s College London. Jess Kerr-Gaffney owns shares in GSK plc and AstraZeneca.Dr Will Lawn has no conflict of interests and disclosures to make.Carl Holvey is a chief clinical pharmacist at Sapphire Medical Clinics. Carl Holvey has no shareholdings in pharmaceutical companies.Ross Coomber is a consultant orthopaedic surgeon, a former director at Sapphire Medical Clinics and a consultant at St George’s Hospital, London. The views expressed are those of the author(s) and not necessarily those of the NHS. Ross Coomber has no shareholdings in pharmaceutical companies.Daniela A Riano Barros is a consultant psychiatrist at Sapphire Medical Clinics and at The South London and Maudsley NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS. Daniela A Riano Barros has no shareholdings in pharmaceutical companies.Urmila Bhoskar is a consultant psychiatrist at Sapphire Medical Clinics. Urmila Bhoskar has no shareholdings in pharmaceutical companies.Gracia Mwimba is a consultant psychiatrist at Sapphire Medical Clinics and Lead Clinician at the National Inpatient Unit for Under 12s in Scotland. She is also consultant psychiatrist in the Paediatric Liaison team for Greater Glasgow and Clyde NHS Board. The views expressed are those of the author(s) and not necessarily those of the NHS. Gracia Mwimba has no shareholdings in pharmaceutical companies.Kavita Praveen is a consultant psychiatrist at Sapphire Medical Clinics. The views expressed are those of the author(s). Kavita Praveen has no shareholdings in pharmaceutical companies.Chris Symeon is a consultant psychiatrist at Sapphire Medical Clinics (London) and at St George’s University Hospitals NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS. Chris Symeon has no shareholdings in pharmaceutical companies.Simmi Sachdeva-Mohan is a consultant psychiatrist at Sapphire Medical Clinics. The views expressed are those of the author(s). Simmi Sachdeva-Mohan has no shareholdings in pharmaceutical companies.Mikael Sodergren is a consultant hepatopancreatobiliary surgeon, a former director at Sapphire Medical Clinics and a consultant at Imperial College NHS Trust, London. He is senior clinical lecturer at Imperial College London and Chief Medical Officer at Curaleaf International. The views expressed are those of the author(s) and not necessarily those of the NHS.James Rucker is a consultant psychiatrist, a former director at Sapphire Medical Clinics (London). James Rucker is an honorary consultant psychiatrist at The South London & Maudsley NHS Foundation Trust and an NIHR Clinician Scientist Fellow at the Centre for Affective Disorders at King’s College London. James Rucker is funded by a fellowship (CS-2017-17-007) from the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. James Rucker has no shareholdings in pharmaceutical companies. James Rucker reviewed this article and made comments.